Latest It Distribution News

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.

SelfWealth Ltd reported a 4% revenue increase and sustained profitability in H1 2025, while advancing a major transformation program and entering a proposed acquisition deal with Bell Financial Group.

FleetPartners Group Limited reported strong FY24 results with record new business writings and assets under management, underpinning a robust growth trajectory and a significant $30 million share buy-back announced for 1H25.

Betashares Mrtn Currie Eqy Inc Fund (EINC) units have been suspended from trading on the ASX as of 22 January 2025, following a prior announcement in December 2024.

Global X Management (AUS) Limited has announced estimated distribution amounts for its Australian-listed ETFs for the period ending January 31, 2025, providing clarity on upcoming income payments.

Australian Foundation Investment Company Limited (AFIC) has announced a fully franked dividend of AUD 0.12 per share for the half-year ending December 2024, accompanied by Dividend Reinvestment and Bonus Security Plans.

Audeara has officially launched its Clinico Sound Earbuds CS1 in Taiwan through a strategic partnership with Clinico Inc., marking a key step in its international expansion and tapping into a growing hearing health market.

Matsa Resources has completed a 767m diamond drill hole at Fortitude North, designed to validate a novel seismic model indicating potential gold mineralisation. Early geological observations support the seismic data, setting the stage for further exploration.

Compumedics has locked in a pivotal five-year contract with Philips Australia, cementing Somfit as the leading device for pharmacy-based sleep testing and underpinning significant SaaS revenue growth through 2028.

Amcor plc has entered a definitive agreement to acquire Berry Global Group in a $9.9 billion all-stock transaction, aiming to create a global packaging leader. The merger, pending shareholder and regulatory approvals, is expected to close mid-2025.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.